R 7025

Drug Profile

R 7025

Alternative Names: Maxy-alpha; R7025; RO 5014583

Latest Information Update: 28 Nov 2007

Price : $50

At a glance

  • Originator Maxygen
  • Class Antivirals; Interferons
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis B; Hepatitis C

Most Recent Events

  • 26 Nov 2007 Discontinued - Phase-I for Hepatitis B treatment in New Zealand (SC)
  • 26 Nov 2007 Discontinued - Phase-I for Hepatitis C treatment in New Zealand (SC)
  • 06 Nov 2007 Final pharmacodynamics, adverse event and pharmacokinetics data from a phase I trial in healthy volunteers presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top